

viz. rural population, rural populations managing Rural Water Supply (RWS), States under Drought Prone Areas Programme (DPAP), Hill Area Development Programme (HADP) and special category hill states in terms of rural areas.

National Health Insurance Scheme

2327. SHRI SANJAY RAUT: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government is considering to make comprehensive National Health Insurance Scheme covering diseases, treatment/surgeries classified and broadbased specialities, by extending the coverage of the scheme to all poor and middle income group persons, specially old age persons upto minimum of 75 years;

(b) if so, the details thereof; and

(c) if not, the reasons therefor?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABI AZAD): (a) to (c) No. However, Ministry of Labour and Employment has launched Rashtriya Swasthya Bima Yojana [RSBY] for workers of Unorganized Sector and their families from 01.04.2008. There is no age limit for coverage of the scheme for dependent parents within the definition of family of five members. Details of the Scheme are at the website of RSBY www.rsby.in.

Deaths due to trial of Pneumonia Vaccine

2328. SHRI DHARAM PAL SABHARWAL: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that there has been some deaths of infants due to trial of Pneumonia Vaccine;

(b) if so, the details in this regard;

(c) whether Government has ordered enquiry of the vaccine trial; and

(d) if so, complete details of enquiry report and action taken against the drug firm?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABI AZAD): (a) to (d) There was a report of serious adverse events regarding death of a subject involved in a clinical trial of 13-valent pneumococcal conjugate vaccine at one of the site in the country. A team was constituted by the Central Drugs Standard Control Organisation (CDSCO) to investigate the matter, which conducted the inspection at the said site. The Inspection revealed various Good Clinical Practices (GCP) violations. Therefore the concerned investigator, sponsor and monitor were issued warning letters asking for corrective actions to be taken by them to prevent such violations in future. The clinical trial remains suspended at all the twelve sites from 06.11.2008 to 22.04.2009. The sponsor submitted various corrective actions taken to ensure GCP compliance. Central Drugs Standard Control Organisation (CDSCO) scrutinized the same